ProfileGDS5678 / 1418721_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 72% 71% 71% 69% 70% 78% 71% 71% 72% 70% 71% 70% 71% 71% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.5181772
GSM967853U87-EV human glioblastoma xenograft - Control 24.4543671
GSM967854U87-EV human glioblastoma xenograft - Control 34.4668171
GSM967855U87-EV human glioblastoma xenograft - Control 44.339569
GSM967856U87-EV human glioblastoma xenograft - Control 54.3194370
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.2149278
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.4720771
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.4509471
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.6283172
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.3684970
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.4221371
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.3402970
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.4823971
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.4542171